Impax Laboratories Inc.’s Parkinson’s disease treatment could be approved by late October, as the Food and Drug Administration accepted the Hayward company’s new drug application.
Impax (NASDAQ: IPXL), which last month said it will hire an undisclosed number of people as it prepares to sell the drug, said Thursday that its IPX-066 was given an FDA decision date of Oct. 21. The drug would be the first product from Impax's branded products unit, Impax Pharmaceuticals.
No comments:
Post a Comment